AIM ImmunoTech is trading at $0.27 (6.4% down) today, extending its weekly decline as the market weighs the impact of recent financing activities and dilution risks.
- The stock is reacting to an ongoing overhang from its June registered direct offering and warrant issuance used to fund clinical trials.
- Traders are cautious ahead of a July 15 special meeting where shareholders will vote on additional share issuances and a potential reverse split.